Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Aesica and EmulTech Develop Sterile Emulsion Technology for Micro Encapsulation

Published: Monday, February 18, 2013
Last Updated: Monday, February 18, 2013
Bookmark and Share
CMO’s Nottingham site first to use EmulTech’s ET4ME technology for GMP production of pharmaceuticals.

Aesica and EmulTech have jointly announced the commercial development of ET4ME - an innovative emulsion technology for product formulation.

ET4ME, a micro-encapsulation technology developed by the EmulTech group (a spin out of Eindhoven University of Technology), utilizes an elegant micro fluidic process to create a measurable micro particulate suspension where particle size is uniform and reproducible.

The technology can be used for a multitude of APIs from small molecules to complex biomolecules, with high levels of batch consistency and reproducibility upon scale up.

By utilizing a closed system, sterile formulations can be achieved, coupled with resistance to oxidative degradation.

The product is already being actively used by an Aesica client to help develop a new dosage form in an acid resistant non-sterile suspension.

However, the partners envisage huge growth in the use of this technology for sterile products following an externally validated process simulation trial (PST).

Over three years in development, and thanks to the creation of an aseptic protocol by Aesica, the technology has applications in the formulation of injectables - in particular depot injections for sustained release, due to the uniform droplet size, loading and morphology.

Formulations have demonstrated improved aqueous stability that will enable our customers to revisit previously abandoned products such as injectables, poor solubility compounds and new formulations of existing products.

Ian Lafferty, site director at Aesica formulation development, commented: We first came across the technology at a conference a few years ago and realized that if we could develop an aseptic process - it’s a tremendous credit to our development team that we could achieve this - it would provide an elegant solution to many compounds. Already, we have started working with several clients to commercialize this technology and there is a tremendous growth opportunity for sterile products and injectables.”

Fränk de Jong, CEO at EmulTech, added: “We knew we had a very innovative proprietary technology and by working with Aesica we now have access to their GMP approved facilities in Nottingham. This coupled with their ability to develop an aseptic process for the technology has enabled us to offer a commercialized solution that has the potential to develop formulations that would previously have been unachievable. Thanks to Aesica the process has been PST validated for steriles and there is a clear emerging demand to develop formulations using this approach.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Aesica Secures Continuing FDA Approval of its Bulk Manufacture and Packaging Sites
FDA inspection results means Aesica will continue to grow its manufacturing and packaging services for pharmaceutical products for the US market.
Tuesday, February 03, 2015
Aesica Appoints VP, Business Development and Business Development Director
Appointment of Detlef Behrens and Sven Wrabletz for finished dose to drive service in Europe and achieve further growth.
Friday, October 31, 2014
Aesica Appoints New Product Release Manager
Company announces appointment of Adam Burgess.
Wednesday, August 20, 2014
Aesica Zwickau Marks 20th Anniversary
Continued growth and expansion of Company’s encapsulation services business.
Saturday, July 19, 2014
Aesica Recruits New Business Development Manager
Appointment of Nadine K. Reuter to aid sales drive across German, Austrian and Swiss Markets.
Thursday, July 03, 2014
Aesica Collaborates with QAD to Meet CFDA’s Shortened Serialization Deadline
The new system was implemented within three months.
Saturday, June 28, 2014
Aesica Successfully Introduces Serialization Services at Italian Site
Initiates commercial production of two product lines for the Chinese market.
Thursday, April 17, 2014
Aesica Led Consortium Wins Technology Strategy Board Grant
Funding secured for the consortium’s project to investigate an industrial biotechnology process to enable improved manufacture of an API.
Tuesday, April 08, 2014
Aesica Completes the Validation of its High Capacity Manufacturing Facility
$45m (USD) has been invested at its Queenborough, UK site.
Saturday, March 15, 2014
Aesica Appoints Ian Muir to Commercial Managing Director Position
Key functions centre on the Group’s commercial business and product pipeline development across API, formulation development and formulated products.
Tuesday, February 04, 2014
Aesica Awarded NEPIC Industry Award
Corporate HR Manager wins NEPIC 2014 Young Achiever Accolade within the Pharmaceutical category.
Thursday, January 30, 2014
Aesica Appoints New Site Manufacturing Manager at Cramlington Facility
Tasked with optimizing performance schedules, including 4 new products for 2014.
Tuesday, November 26, 2013
Aesica Recruits New East Coast Business Development Manager
Appointment of Baali Muganga to spearhead growth in contract manufacturing market share across the US region.
Tuesday, October 29, 2013
Aesica Target Development Services at Growing Inhalation Market
CDMO’s Nottingham site a hot bed of innovation with unique spray drying, powder filling and dry powder inhaler technology.
Wednesday, October 16, 2013
Aesica Unveils a New High Capacity Manufacturing Facility
New facility specifically built to produce a solid dose medication for treating Type 2 diabetes in adults.
Thursday, September 19, 2013
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Study Questions Presence in Blood of Heart-Healthy Molecules from Fish Oil Supplements
A new study from the Perelman School of Medicine at the University of Pennsylvania questions the relevance of fish oil-derived SPMs and their purported anti-inflammatory effects in humans.
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Key Player in Diabetic Kidney Disease Revealed
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!